A phase II study of mitozantrone in advanced carcinoma of the ovary.
A total of 37 patients with advanced epithelial ovarian cancer were treated with single-agent mitozantrone at a dose of 12-16 mg/m2. All patients had received previous chemotherapy, including a platinum compound in 36. In all, 35 patients were evaluable for response. One patient (3%) achieved a partial response lasting 4 months. Treatment was well tolerated, and at the doses used in this study significant bone marrow suppression was uncommon. Our results suggest that mitozantrone has only minimal activity in previously treated ovarian cancer. However, the possibility of its useful activity in first-line treatment or at higher doses has not been excluded.
Coleman
R
R
Department of Medical Oncology, Guy's Hospital, London, UK.
Clarke
J
J
Gore
M
M
Wiltshaw
E
E
Slevin
M
M
Harper
P
P
D000328:Adult; D000368:Aged; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality
D008942:Mitoxantrone